文献速递糖尿病甲状腺疾病

二甲双胍对甲状腺癌发生的保护作用:韩国一项基于人群的研究

Protective Effect of Metformin Against Thyroid Cancer Development: A Population-Based Study in Korea.
PubMed 文献 · Thyroid · 2018-06-29

该回顾性队列研究利用韩国国民健康保险理赔数据库,匹配128453名二甲双胍使用者和128453名非使用者,分析甲状腺癌发病率。结论认为二甲双胍似乎与甲状腺癌发生的预防作用相关,但在治疗早期无效。

要点

  • 甲状腺癌风险随二甲双胍累积剂量和持续时间的增加而显著降低。
  • 二甲双胍在治疗早期对甲状腺癌发生未见保护作用。

核心结论

  • 二甲双胍似乎与甲状腺癌发生的预防作用相关,但在治疗早期无效。
  • 考虑到肥胖患病率增加和胰岛素抵抗在癌症发生中的作用,二甲双胍可能因其双重抗糖尿病和抗肿瘤作用而成为首选治疗。

研究设计与样本

  • 回顾性队列研究,使用韩国国民健康保险理赔数据库。
  • 匹配分析了128453名二甲双胍使用者和128453名非使用者,比较甲状腺癌发病率。
  • 二甲双胍使用者根据累积剂量或治疗持续时间分为最低、中间和最高三分位组。

主要发现

  • 非使用者甲状腺癌发病率为每10万人年51.6例;使用者中,累积剂量<529000 mg组为84.5,529000-1007799 mg组为20.6,>1007799 mg组为6.3;治疗持续时间<1085天组为86.3,1085-2094天组为20.3,>2094天组为4.7。
  • 二甲双胍使用者甲状腺癌的风险比随剂量和治疗持续时间显著降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metformin, the most widely used drug for type 2 diabetes, has recently attracted attention with regard to its antitumor activity. However, clinical studies have yielded conflicting results regarding the association between metformin and thyroid cancer development, despite its antitumor effect in preclinical studies. METHODS: This is a retrospective cohort study using the Korean National Health Insurance claim database. Matched populations of 128,453 metformin users and 128,453 non-users were analyzed for thyroid cancer incidence. Metformin users were categorized into lowest, middle, and highest tertiles according to cumulative dose or duration of metformin therapy. RESULTS: Thyroid cancer developed in 340 (0.26%) metformin users and 487 (0.38%) non-users during a mean follow-up of 7.2 years (hazard ratio = 0.69 [confidence interval 0.60-0.79]; p < 0.001). The incidence of thyroid cancer per 105 person-years was 51.6 in metformin non-users. For metformin users, the incidence was 84.5 for <529,000 mg, 20.6 for 529,000-1,007,799 mg, and 6.3 for >1,007,799 mg; 86.3 for <1085 days, 20.3 for 1085-2094 days, and 4.7 for >2094 days for duration of therapy. The hazard ratio for thyroid cancer decreased significantly in metformin users as a function of dose and duration of metformin therapy. CONCLUSIONS: Metformin appears to be associated with a preventive effect on thyroid cancer development in a nationwide population-based study, but is not effective in the early phase of treatment. Considering the increasing prevalence of obesity and the role of insulin resistance in the development of cancer, metformin might be the preferred treatment for its dual anti-diabetic and antitumor effects.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Cho YY, Kang MJ, Kim SK, et al. Protective Effect of Metformin Against Thyroid Cancer Development: A Population-Based Study in Korea. Thyroid. 2018. PMID: 29808777. doi:10.1089/thy.2017.0550

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。